Cover Image
Read Now

WHO treatment guidelines for isoniazid-resistant tuberculosis supplement to the WHO treatment guidelines for drug-resistant tuberculosis

The emergence of drug-resistant TB (tuberculosis) is a major global health concern, which threatens the ambitious goals and progress set under the End TB Strategy. Isoniazid-resistant TB, which is present in 8% of TB cases worldwide, reduces treatment success in patients treated with the standard 6-...

Full description

Bibliographic Details
Corporate Author: World Health Organization
Format: eBook
Language:English
Published: Geneva World Health Organization 2018, [2018]
Subjects:
Antitubercular Agents / Standards
Evidence-based Medicine
Extensively Drug-resistant Tuberculosis / Drug Therapy
Isoniazid / Therapeutic Use
Treatment Outcome
Rifampin / Therapeutic Use
Antitubercular Agents / Therapeutic Use
Online Access:
Collection: National Center for Biotechnology Information - Collection details see MPG.ReNa
Description
Summary:The emergence of drug-resistant TB (tuberculosis) is a major global health concern, which threatens the ambitious goals and progress set under the End TB Strategy. Isoniazid-resistant TB, which is present in 8% of TB cases worldwide, reduces treatment success in patients treated with the standard 6-month first-line regimen. The new WHO recommendations for the treatment of isoniazid-resistant, rifampicin-susceptible TB are based upon a review of evidence from patients treated with such regimens by a Guideline Development Group in conformity with WHO requirements for evidence-based policies
Item Description:"The End TB Strategy.". - "WHO/CDS/TB/2018.7"--PDF t.p. verso. - Supplement to WHO treatment guidelines for drug-resistant tuberculosis. Geneva, Switzerland : World Health Organization, [2016]
Physical Description:1 PDF file (xi, 31 pages)
ISBN:9789241550079

Similar Items